These increases suggest that a large tumor macrophage population promotes poor clinical outcome by potentiating aggressive CD30+ tumor cells in a subset of HL patients, and some of these CD30+ cells may express FGF2 and SDC1. Here, FGF2 is linked to Hodgkins lymphoma.